

*School of Natural Sciences and Mathematics*

***Reduced Expression of Foxp1 as a  
Contributing Factor in Huntington's Disease***

**UT Dallas Author(s):**

Anto Sam Crosslee Louis Sam Titus  
Santosh R.D'Mello

**Rights:**

CC BY 4.0 (Attribution)  
©2017 The Authors

**Citation:**

Titus, Anto Sam Crosslee Louis Sam, Tanzeen Yusuff, Marlene Cassar, Elizabeth Thomas, et al. 2017. "Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease." *Journal of Neuroscience* 37(27): 6575-6587.

*This document is being made freely available by the Eugene McDermott Library of the University of Texas at Dallas with permission of the copyright owner. All rights are reserved under United States copyright law unless specified otherwise.*

# Reduced Expression of *Foxp1* as a Contributing Factor in Huntington's Disease

 Anto Sam Crosslee<sup>1</sup>, Louis Sam Titus<sup>1</sup>, Tanzeen Yusuf<sup>2</sup>,  Marlène Cassar<sup>3</sup>, Elizabeth Thomas<sup>4</sup>, Doris Kretschmar<sup>3</sup>, and Santosh R. D'Mello<sup>1,2</sup>

<sup>1</sup>Department of Molecular and Cell Biology, University of Texas at Dallas, Richardson, Texas 75080, <sup>2</sup>Department of Biological Sciences, Southern Methodist University, Dallas, Texas 75275, <sup>3</sup>Oregon Institute of Occupational Health Sciences, Oregon Health and Science University, Portland, Oregon 97239, and <sup>4</sup>Department of Neuroscience, Scripps Research Institute, La Jolla, California 92037

Huntington's disease (HD) is an inherited neurodegenerative disease caused by a polyglutamine expansion in the huntington protein (*htt*). The neuropathological hallmark of HD is the loss of neurons in the striatum and, to a lesser extent, in the cortex. *Foxp1* is a member of the Forkhead family of transcription factors expressed selectively in the striatum and the cortex. In the brain, three major *Foxp1* isoforms are expressed: isoform-A (~90 kDa), isoform-D (~70 kDa), and isoform-C (~50 kDa). We find that expression of *Foxp1* isoform-A and -D is selectively reduced in the striatum and cortex of R6/2 HD mice as well as in the striatum of HD patients. Furthermore, expression of mutant *htt* in neurons results in the downregulation of *Foxp1*. Elevating expression of isoform-A or -D protects cortical neurons from death caused by the expression of mutant *htt*. On the other hand, knockdown of *Foxp1* promotes death in otherwise healthy neurons. Neuroprotection by *Foxp1* is likely to be mediated by the transcriptional stimulation of the cell-cycle inhibitory protein *p21<sup>Waf1/Cip1</sup>*. Consistently, *Foxp1* activates transcription of the *p21<sup>Waf1/Cip1</sup>* gene promoter, and overexpression of *Foxp1* in neurons results in the elevation of *p21* expression. Moreover, knocking down of *p21<sup>Waf1/Cip1</sup>* blocks the ability of *Foxp1* to protect neurons from mutant *htt*-induced neurotoxicity. We propose that the selective vulnerability of neurons of the striatum and cortex in HD is related to the loss of expression of *Foxp1*, a protein that is highly expressed in these neurons and required for their survival.

**Key words:** *Foxp1*; Huntington's disease; neurodegeneration; neuroprotection

## Significance Statement

Although the mutant huntingtin gene is expressed widely, neurons of the striatum and cortex are selectively affected in Huntington's disease (HD). Our results suggest that this selectivity is attributable to the reduced expression of *Foxp1*, a protein expressed selectively in striatal and cortical neurons that plays a neuroprotective role in these cells. We show that protection by *Foxp1* involves stimulation of the *p21<sup>Waf1/Cip1</sup>* (*Cdkn1a*) gene. Although three major *Foxp1* isoforms (A, C, and D) are expressed in the brain, only isoform-A has been studied in the nervous system. We show that isoform-D is also expressed selectively, neuroprotective and downregulated in HD mice and patients. Our results suggest that *Foxp1* might be an attractive therapeutic target for HD.

## Introduction

Huntington's disease (HD) is an inherited neurodegenerative disease caused by an abnormal expansion of a CAG repeat in the

first exon of the huntingtin gene, resulting in a mutant protein with a polyglutamine expansion (Zuccato et al., 2010). Although mutant huntingtin (mut-*Htt*) is ubiquitously expressed in the brain, in both neurons and glial cells, neurodegeneration in HD is mostly restricted to medium spiny neurons (MSNs) of the striatum and, to a lesser degree, some neurons in layers II, V, and VI of the cortex (Zuccato et al., 2010). We propose that a key factor in the selective vulnerability of the striatum and cortex is the altered expression of a survival-promoting gene called *Foxp1*, which is expressed most highly in neurons of the striatum and, to a lower level, in the cortex (Desplats et al., 2006, 2008). *Foxp1* is one of

Received Nov. 23, 2016; revised May 8, 2017; accepted May 11, 2017.

Author contributions: A.S.C.L.S.T., T.Y., M.C., D.K., and S.R.D. designed research; A.S.C.L.S.T., T.Y., and M.C. performed research; A.S.C.L.S.T. and E.T. contributed unpublished reagents/analytic tools; A.S.C.L.S.T., M.C., and D.K. analyzed data; A.S.C.L.S.T., D.K., and S.R.D. wrote the paper.

This work was supported by NIH Grant NS040408 to S.R.D. We thank Lulu Wang for technical assistance. We are grateful to Troy Littleton (Massachusetts Institute of Technology) and Dimitri Krainc (Northwestern University) for providing *Htt* and mutant-*Htt* plasmids. We thank Peter Detloff (University of Alabama at Birmingham) for the knock-in mouse samples. We also thank Ming Zhang (Northwestern University) for providing the *p21<sup>Waf1/Cip1</sup>* promoter luciferase construct.

Correspondence should be addressed to Dr. Santosh R. D'Mello, Department of Biological Sciences, Southern Methodist University, Dedman Life Sciences Building, 6501 Airline Road, Dallas, TX 75275. E-mail: sdmello@smu.edu.

DOI:10.1523/JNEUROSCI.3612-16.2017  
Copyright © 2017 the authors 0270-6474/17/376575-13\$15.00/0

four members of the *Foxp* subfamily of Forkhead (FOX) proteins (Bowers and Konopka, 2012). Whereas *Foxp1*, *Foxp2*, and *Foxp4* are expressed in the brain, *Foxp3* is not (Tam et al., 2011; Le Fevre et al., 2013). Mutations of *Foxp1* are linked to speech and language disorders, delays in motor development, autism, and mental retardation (Hamdan et al., 2010; Horn et al., 2010; Bowers and Konopka, 2012; Le Fevre et al., 2013; Bacon et al., 2014; Sollis et al., 2016). MRI scans have revealed abnormally enlarged ventricles in humans with *Foxp1* mutations raising the possibility of neuronal loss (Pariani et al., 2009).

Conventional *Foxp1* knock-out mice (*Foxp1*<sup>−/−</sup>) die at embryonic day 14.5 (E14.5) with cardiac abnormalities (Wang et al., 2004). Analyses of *Foxp1*<sup>+/−</sup> mice have revealed a role in motor neuron diversification, connectivity, and differentiation of stem cells into dopaminergic neurons (Dasen et al., 2008; Konstantoulas et al., 2010). Knockdown of *Foxp1* in the developing cortex has revealed a role in regulating neuronal migration and morphogenesis (Li et al., 2015). These observations demonstrate the importance of *Foxp1* in brain development. However, *Foxp1* is expressed throughout adulthood, but little is known about its function in the adult brain. Within the striatum, *Foxp1* is expressed in MSNs with no expression in striatal interneurons (Tamura et al., 2004). Brain-specific deletion of *Foxp1* causes pronounced reduction in striatal volume (Bacon et al., 2014), which was suggested to be attributable to reduced proliferation of neuronal progenitors. Interestingly, the striatal reduction was not observed until 3 weeks of age. Since neurogenesis in the striatum is complete before this time, it is possible that degeneration is responsible for the smaller striatum.

The *Foxp1* gene can be alternatively spliced to produce multiple isoforms, the largest of which is ~90 kDa (also referred to as isoform-A). These isoforms are expressed tissue-specifically and may have distinct functions (Brown et al., 2008; Green et al., 2009; Santos et al., 2011). For example, *ES-Foxp1*, an isoform expressed only in embryonic stem cells and referred to as isoform-B, contributes to the maintenance of stem cell pluripotency (Gabut et al., 2011). Almost all published work on *Foxp1* has focused on isoform-A. Although the brain expresses two other major isoforms of ~50 and ~70 kDa molecular weight (isoform-C and -D, respectively), the significance of these *Foxp1* isoforms for neurons or the brain is not known.

We have investigated the role of *Foxp1* in the regulation of neuronal survival. We describe that *Foxp1* expression is reduced in the R6/2 mouse model of HD and in the striatum of HD patients. Forced expression of mut-*Htt* results in a downregulation of *Foxp1* expression, whereas elevating expression of either isoform-A or -D inhibits mut-*Htt* neurotoxicity. To our knowledge, this is the first report demonstrating a protective role of *Foxp1* in HD. Furthermore, this is the first study that investigates the function of the smaller isoforms of *Foxp1* in the nervous system. We suggest that *Foxp1* protects neurons by stimulating the expression of *p21<sup>Waf1/Cip1</sup>*, a cell-cycle regulatory protein with well documented neuroprotective effects.

## Materials and Methods

**Materials.** Unless stated otherwise, all tissue culture media were purchased from Invitrogen, and chemicals and reagents were purchased from Sigma-Aldrich. Poly-L-lysine for primary neuronal cultures was purchased from Trevigen. Antibodies used in this study are as follows: Foxp1 (from three sources: Cell Signaling Technologies, which recognizes Foxp1 amino acids adjacent to Leu584, catalog #D35D10, RRID: AB\_10545755; Abcam, catalog #ab134055, RRID:AB\_2632402; Bethyl Laboratories, which recognizes Foxp1 amino acids 627–677, catalog #A302-620A, RRID:AB\_10555081), FLAG (Sigma-Aldrich, catalog #F1804, RRID:AB\_262044),  $\alpha$ -Tubulin (Sigma-Aldrich, catalog #T9026, RRID:

AB\_477593), ERK1/2 (Cell Signaling Technology, catalog #9102, RRID: AB\_330744), GFP (Santa Cruz Biotechnology, mouse GFP, catalog #sc-9996a, RRID:AB\_627695; and rabbit GFP, catalog #sc-8334, RRID: AB\_641123), p21 (BD Pharmingen, catalog #556430, RRID:AB\_396414), and HRP-conjugated secondary antibodies (Pierce). Immunocytochemistry secondary antibodies Dylight 594 (catalog #115-585-146, RRID:AB\_2338881) and Alexa Fluor 488 (catalog #115-545-146, RRID:AB\_2307324), were obtained from Jackson ImmunoResearch Laboratories. Human caudate tissue samples from both male and female HD patients along with unaffected controls were obtained from NIH NeuroBioBank.


**Expression plasmids.** FLAG-tagged *Foxp1* plasmid pCMV10-mFoxp1 was a gift from Benjamin Blencowe (University of Toronto, Ontario, Canada) (Addgene plasmid 35170). GFP-tagged *Foxp1* plasmids and *Foxp1* isoform-D were cloned in our laboratory. GFP- and RFP-tagged *Htt* plasmids were a kind gift from Dr. Troy Littleton (Massachusetts Institute of Technology, Cambridge, MA). The *p21<sup>Waf1/Cip1</sup>* promoter luciferase construct was a kind gift from Dr. Ming Zhang (Northwestern University Feinberg School of Medicine, Chicago, IL). FLAG-tagged *p21<sup>Waf1/Cip1</sup>* was a gift from Mien-Chie Hung (The University of Texas MD Anderson Cancer Center, Houston, TX) (Addgene plasmid 16240).

**Culturing, treatment, and transfection of cerebellar granule neurons.** Cerebellar granule neurons (CGNs) were cultured from 7- to 9-d-old Wistar rats and plated in Eagle's basal medium supplemented with 10% FBS, 25 mM KCl, 2 mM glutamine, and 0.2% gentamycin, as described previously (D'Mello et al., 1993). For 4- or 24-well dishes, cells were plated at a density of  $1 \times 10^6$ /well, and for 60 mm dishes, they were plated at a density of  $10 \times 10^6$ . The antimitotic agent cytosine arabinofuranoside was added 16–20 h later at a concentration of 10  $\mu$ M. Treatment with high-potassium (HK) or low-potassium (LK) medium was performed 5 d after plating by switching the cultures to serum-free medium with 25 mM KCl (HK) or without KCl (LK) supplementation. Cell death was quantified by 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) staining as described previously (Dastidar et al., 2011; Bardai et al., 2013). Cells with condensed or fragmented nuclei were scored as dead. Transfection of CGN cultures was performed 4–5 d after plating using the calcium phosphate method as described previously (Dastidar et al., 2011; Bardai et al., 2013). Unless mentioned otherwise, neurons were switched to HK or LK treatment 24 h after transfection and viability quantified 24 h later using immunocytochemistry to detect transfected cells. The proportion of transfected cells undergoing apoptosis was quantified by DAPI staining. The viability is normalized to that of the neurons transfected with GFP in the HK condition. Transfections for each experiment were performed in duplicates, and the experiments were repeated at least three times.


**Culturing, treatment, and transfection of embryonic cortical neurons.** Cortical neurons were cultured from E17–E18 Wistar rat embryos as we have previously described (Dastidar et al., 2011; Bardai et al., 2013). The neurons were plated in Neurobasal medium with B27 supplement. Transfection was performed on day 5 of culture using the calcium phosphate method, and after 24 h of transfection, the neurons were subjected to apoptotic stimuli by adding 1 mM homocysteic acid (HCA), which induces oxidative stress (Ratan et al., 1994). After 16–18 h, the proportion of cells undergoing apoptosis was quantified by DAPI staining, and viability was normalized to that of the neurons transfected with GFP in the untreated condition. Transfections for each experiment were performed in duplicates, and the experiments were repeated at least three times.

**Culturing of cortical glial cells.** The cortex was isolated from postnatal days 2–3 rat pups and placed in HBSS buffer. The tissue was then dissociated by the addition of trypsin, followed by mechanical dissociation. The trypsin was then neutralized by adding serum, and the cells were plated in DMEM with 10% FBS. The cell culture medium was replaced every 2 d, and the cells were subcultured when they reached 80% confluence. After two passages, the neurons were eliminated, and the cortical glial cells were used for the experiments.

**Culture and transfection of cell lines.** Cell lines HEK293T (catalog #CRL-11268, RRID: CVCL\_1926) and N2A (catalog #CCL-131, RRID: CVCL\_0470) were obtained from ATCC. Each were cultured in DMEM supplemented with 10% FBS and transfected with Lipofectamine 2000 (Invitrogen) in Opti-MEM medium according to the manufacturer's



**Figure 1.** Foxp1 expression levels in different brain regions. Foxp1 protein expression levels in the mouse cortex (CTX), cerebellum (CBM), olfactory bulb (OB), hippocampus (HIP), striatum (STR), and other brain parts (OBP) at 12 months of age, analyzed using Foxp1 antibody (Bethyl Laboratories).  $\alpha$ -Tubulin was used as a loading control.



**Figure 2.** Foxp1 expression levels change in neurons under apoptotic stress. **A**, Foxp1 RNA expression analysis in cortical neurons subjected to apoptotic conditions. mRNA was prepared from cortical neurons treated with 1 mM HCA for 3 and 6 h. *c-jun* is used as a marker for apoptosis, and actin is used as a normalization control. **B**, Quantification of Foxp1 RNA expression levels normalized to the expression levels of  $\beta$ -actin.  $*p < 0.05$  ( $n = 4$ ). **C**, Foxp1 protein levels in cortical neurons under apoptotic stress from HCA treatment. Protein lysates were prepared at 3, 6, and 9 h of HCA treatment and subjected to Western blotting using Foxp1 antibody (Cell Signaling Technology). Erk1/2 is used as a loading control. **D**, Quantification of Foxp1 protein levels in cortical neurons treated with HCA. Foxp1 protein levels were normalized to the expression levels of Erk1/2.  $*p < 0.05$  ( $n = 4$ ). **E**, Foxp1 protein levels in CGNs subjected to apoptotic stress by LK treatment. Protein lysates were collected at 3 and 6 h of treatment and subjected to Western blotting using Foxp1 antibody (Cell Signaling Technology). Erk1/2 is used as a loading control. **F**, Quantification of Foxp1 protein expression levels normalized with expression levels of ERK. Not significant,  $n = 3$ . UN, Untreated.

instructions. Transfection efficiency was  $\sim 70$ – $80\%$  in N2A cells and  $\sim 80$ – $90\%$  in HEK293T cells.

**Western blot analysis.** Cell culture and tissue samples were lysed, protein concentration was quantified, and Western blots were performed as described previously (Dastidar et al., 2011; Bardai et al., 2013). Typically, 50  $\mu$ g of protein was used per lane and transferred following PAGE to PVDF membrane. After blocking with milk, membranes were incubated overnight in primary antibodies that were used at a 1:500 to 1:1000 dilution in TBST with 5% BSA. Appropriate secondary antibodies were used at 1:20,000 dilution in 5% milk in TBST for 1 h. Immunoreactivity was detected by enhanced chemiluminescence (GE Healthcare Biosciences) according to the manufacturer's directions.

**cDNA synthesis and RT-PCR.** RNA was extracted by lysing the cells in TRIzol (Invitrogen) and following the manufacturer's instructions. The RNA extracted was quantified, and 3  $\mu$ g of RNA was used to generate cDNA using the Superscript First Strand Synthesis System (Invitrogen). GoTaq Green Master Mix (Promega) was used to perform PCR; initially, 1  $\mu$ l of cDNA was used to check the expression levels of actin, and the quantity of cDNA used was adjusted according to actin normalization.

The following primers were used for amplification: Foxp1 MR For: 5'-GGACGATAG AAGCACAGCTCAATGT-3' and Foxp1 MR Rev: 5'-ATGGGCACGTTGTATTGTCT-GAGT-3'; Foxp1 HUM For: 5'-GTTCCCGTGT-CAGTGGCTAT-3' and Foxp1 HUM Rev: 5'-TGTTGATTGTTGCCTGTGGTT-3'; Actin For: 5'-GAGAGGGAAATCGTGCCTGAC-3' and Actin Rev: 5'-CATCTGCTGGAAGGTGGACA-3'; *c-jun* For: 5'-GATGGAACGAC CTTC-TACG-3' and *c-jun* Rev: 5'-GTTGAAGTTGCT GAGGTTGG-3'; p21 For: 5'-CCTGGTGAT GTCCGACCTGTTCC-3' and p21 Rev: 5'-GCGCTTGAGTGATAGAAATCTG-3'.

**shRNA-mediated knockdown.** Five shRNA constructs were obtained from Sigma-Aldrich to be used for knockdown analysis of Foxp1 [TRCN0000072003 (shA), TRCN0000072004 (shB), TRCN0000072005 (shC), TRCN0000072006 (shD), and TRCN0000321549 (shE)]. For knocking down the expression of *p21<sup>Waf1/Cip1</sup>* shRNA constructs, TRCN000042585 (sh1) and TRCN000042587 (sh2), from Sigma-Aldrich, were used. The pLKO.1-TRC control vector that encodes an 18 bp nonhairpin-forming insert purchased from Addgene (catalog #10879) was used as control. The shRNAs were transfected into cortical neurons on day 4 *in vitro* and allowed to express for 72 h before quantifying the viability of transfected cells. The transfected cells were visualized by cotransfecting the shRNA with EGFP in a ratio of 6.5:1. The viability of these transfected cells was quantified by DAPI staining.

**Site-directed mutagenesis.** Foxp1 mutant plasmids Foxp1 $\Delta$ LZ [lacking the leucine zipper (LZ) region] and Foxp1 $\Delta$ FH [lacking the Forkhead (FH) domain] were generated using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) following the manufacturer's instructions. The GFP-tagged Foxp1 plasmid with the CMV promoter was used as the template. The plasmids were sequenced to confirm the mutations and expressed in HEK293 cells to confirm protein expression. The following primers were used to generate the mutants: Foxp1 $\Delta$ LZ-376–397-For: 5'-GTAGAGTACAAATGCAGGTTTCATGTGAAGTCTACA-




GAACC-3'; *Foxp1*ΔLZ-376–397-Rev: 5'-GG-TTCTGTAGACTTCACATGAACCTGCATT-TGTACTCTAC-3'; *Foxp1*ΔFH-493–583-For: 5'-GAATTTTATAAGAACGCGGAAGTTAT-TAAAAACATGCAGAGCAGCCAC-3'; *Foxp1*ΔFH-493–583-Rev: 5'-GTGGCTGCTCTG-CATGTTTATAATAACTTCCGCGTTCTTAT-AAAATTC-3'.

**Adenovirus generation.** Adenovirus was generated using the ViraPower Adenovirus Expression kit from Invitrogen. The *Foxp1* gene was cloned into the pDONR 221 shuttle vector, which was then transferred into the adenoviral vector pAd/CMV/V5-DEST. The gene-containing vector was then linearized with *PacI* and transfected into HEK293A cells for virus amplification. The crude lysate was then freeze thawed four times, followed by CsCl gradient ultracentrifugation to purify the virus. The approximate titer of the virus ranged from  $10^{10}$  to  $10^{11}$  pfu/ml. CGNs and cortical neuron cultures were infected with adenovirus on day 5 *in vitro*, and protein/gene expression changes were analyzed 36–48 h later. The transduction efficiency of ~25–30% was observed using the adenovirus in neurons.

**Bromodeoxyuridine assay.** Bromodeoxyuridine (BrdU) incorporation assays were performed as described previously (Majdzadeh et al., 2008; Mallick and D'Mello, 2014). Briefly, cell lines were transfected with the experimental plasmids by Lipofectamine 2000, and 22 h later, BrdU (200  $\mu$ M) was added to the cell culture medium and incubated for 2 h. The cells were fixed with 4% paraformaldehyde, and immunocytochemistry was performed. The dividing cells (BrdU-positive cells) were identified using a monoclonal mouse antibody against BrdU (catalog #B8434, Sigma), whereas transfected cells were identified with GFP or FLAG antibodies. The proportion of transfected cells that were BrdU positive was quantified.

**Luciferase assay for transcriptional activity.** A total of 3.75  $\mu$ g *p21<sup>Waf1/Cip1</sup>* luciferase reporter plasmid with firefly luciferase and 0.25  $\mu$ g of renilla luciferase were transfected into N2A cells along with 4  $\mu$ g of experimental plasmids. After 24 h, the cells were lysed with Passive Lysis Buffer, and the transcriptional assay was performed using the Dual-Luciferase reporter assay system (catalog #E1910, Promega). First, the substrate for firefly luciferase was added and the relative luminescence units (RLU) were measured in a luminometer, followed by the addition of Stop and Glow Reagent (which has a substrate for renilla luciferase), and then RLU were measured for renilla. The RLU values of firefly luciferase, which were normalized with renilla, were used to calculate the fold induction.

**CRISPR knockdown.** CRISPR plasmids were constructed by cloning the target sequence of *Foxp1* in vector PX458 (Addgene plasmid 48138), which has the cas9 gene in the backbone. The oligos for target sequences were melted in a hotplate, allowed to anneal at room temperature, and cloned into the sgRNA scaffold of PX458 digested with *BbsI*. The oligo sequences are as follows: Foxp1-CPR-1 For: 5'-CACCGTGACACTCG-GTCCAACGGAG-3'; Foxp1-CPR-1 Rev: 5'-AAACCTCCGTTGGAC-CGAGTGTAC-3'; Foxp1-CPR-2 For: 5'-CACCGCGAGAGCTGTG-CCATTGGTAG-3'; Foxp1-CPR-2 Rev: 5'-AAACCTACCAATGGA-CAGCTCTCGC-3'; Foxp1-CPR-3-For: 5'-CACCGTCTTCAGGTTT-CCGTGTACAG-3'; Foxp1-CPR-3-Rev: 5'-AAACCTGACACGGGAA-CCTGAAGAC-3'.




**Figure 3.** Foxp1 expression levels in Huntington's disease models. **A**, Western blotting analysis of Foxp1 in various brain regions of wild-type (WT) and R6/2 transgenic littermates of mice at different ages using Foxp1 antibody (Bethyl Laboratories). **B**, **C**, Western blotting analysis of Foxp1 in various brain regions of WT and R6/2 mice at 2 weeks of age (**B**) and at 12 weeks of age (**C**) using Foxp1 antibody (Cell Signaling Technology). **D**, Quantification of protein expression levels of Foxp1 (isoform-A plus isoform-D) in different brain regions of WT and R6/2 mice at 12 weeks of age. Erk1/2 was used as a normalization control. \*\*\* $p < 0.001$  compared with expression levels in WT mice ( $n = 3$ ). **E–G**, Western blotting analysis of Foxp1 expression levels in cortex (**E**), striatum (**F**), and cerebellum (**G**) of knock-in mice having various lengths of polyglutamine expansion in the Huntingtin gene using Foxp1 antibody (Abcam). Tubulin is used as a loading control. **H**, Quantification of Foxp1 protein levels in various brain regions of *Htt* knock-in mice normalized with expression levels of Tubulin. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  ( $n = 3$ ). CTX, Cortex; CBM, cerebellum; STR, striatum; OBP, other brain parts.

**Table 1. Decreased Foxp1 mRNA levels reported in published datasets from human HD caudate and HD mouse models**

Model	Age/grade	Region	Gene ID	Log2 FC	<i>p</i> value	Reference
Human	Grades 0–4	Caudate	<i>FOXP1</i>	−0.578	2.57E-10	Hodges et al. (2006)
R6/1	6 months	Striatum	<i>Foxp1</i>	−1.152	1.70E-03	Desplats et al. (2006)
R6/2-Q150	12 weeks	Striatum	<i>Foxp1</i>	−0.775	3.94E-06	Kuhn et al. (2007)
R6/2-Q150	12 weeks	Striatum	<i>Foxp1</i>	−0.304	3.80E-03	Tang et al. (2011)
Hdh <sup>Q92</sup>	18 months	Striatum	<i>Foxp1</i>	−1.737	1.02E-02	Kuhn et al. (2007)
Yac128	12 months	Striatum	<i>Foxp1</i>	−0.403	4.31E-02	Kuhn et al. (2007)
CHL2 (Hdh <sup>Q150</sup> )	22 months	Striatum	<i>Foxp1</i>	−0.979	7.55E-06	Kuhn et al. (2007)
Het-KI-Q111	10 months	Striatum	<i>Foxp1</i>	−0.223	5.10E-04	Langfelder et al. (2016)
Het-KI-Q140	10 months	Striatum	<i>Foxp1</i>	−0.341	1.06E-07	Langfelder et al. (2016)
Het-KI-Q175	10 months	Striatum	<i>Foxp1</i>	−0.325	4.09E-07	Langfelder et al. (2016)

FC, Fold change.



**Figure 4.** *FOXP1* mRNA and protein expression in caudate of HD patients. **A, B**, RNA extracted from caudate of age-matched normal male individuals and HD patients (**A**) or normal female individuals and HD patients (**B**) was subjected to RT-PCR analysis using primers amplifying regions common to all the isoforms of *FOXP1*.  $\beta$ -ACTIN was used as the normalization control. **C, D**, Foxp1 protein expression levels in normal male individuals and HD patients (**C**) or normal female individuals and HD patients (**D**) analyzed by Western blotting using Foxp1 antibody (Abcam).  $\alpha$ -TUBULIN was used as the loading control, and a downregulation of isoform-A and -D and upregulation of isoform-C was observed. **E, F**, Quantification of *Foxp1* RNA expression levels (**E**) and protein expression levels (**F**) in caudate of normal individuals and HD patients. **G**, Western blotting analysis of Foxp1 protein levels using Foxp1 antibody (Abcam) in N2A neuroblastoma cells and in cortical neurons (CN), after infection with GFP or Q138 adenovirus. **H**, Foxp1 isoform-A is shown, and the expression level in cortical neurons is quantified.

The CRISPR plasmids were transfected into N2A cells by Lipofectamine 2000 to check for efficiency of knockdown by Western blotting and into primary neurons by the calcium phosphate method. Seventy-two hours later, immunocytochemistry was performed with the GFP antibody to detect the transfected cells, and the viability of the neurons was determined using DAPI as described previously.

**Fly stocks and genetics.** Mammalian GFP-tagged full-length *Foxp1* isoform-A and *Foxp1* isoform-D were excised from mammalian expression vectors and subcloned into the NotI-XbaI site of the modified fly upstream activation sequence (UAS) expression vector (Exelixis). The expression vectors containing the *Foxp1* gene were then microinjected into flies by BestGene as part of a fee-for-service arrangement to obtain transgenic flies. The UAS-*Foxp1A* and UAS-*Foxp1D* flies were recombined with *Appl-GAL4* to drive their expression in all neurons. The GMR-*Htt* Q120 flies were obtained from the Bloomington Stock Center (Indiana University Bloomington). All flies were maintained and crosses were set at room temperature (25°C) in standard *Drosophila melanogaster* medium.

**Paraffin sections.** Paraffin sections for determining retinal degeneration were prepared as described by Bettencourt da Cruz et al. (2005). Briefly, whole flies were fixed in Carnoy's solution and dehydrated in an

ethanol series, followed by incubation in methyl benzoate before embedding in paraffin. Sections were cut at 7  $\mu$ m and imaged using the auto-fluorescence caused by the dispersed eye pigment.

**Fast phototaxis.** Fast phototaxis assays were conducted in the dark using the counter-current apparatus described by Benzer (1967) and a single light source. A detailed description of the experimental conditions has been published previously (Strauss and Heisenberg, 1993). Flies were starved for 4 h but had access to water before being tested. Five consecutive tests were performed in each experiment with a time allowance of 6 s to make a transition toward the light and into the next vial.

**The R6/2 transgenic mouse model of HD.** Female C57BL/6J ovarian transplant mice hemizygous for exon 1 of the mutant *Htt* gene containing  $120 \pm 5$  CAG repeats were bred with wild-type C57BL/6J males (The Jackson Laboratory), and the genotype of the progeny was analyzed by PCR. Transgenic mice (R6/2) and their wild-type gender-matched littermates were killed, and the brains were dissected. Cortex, striatum, cerebellum, and the rest of the brain/other brain parts were separated to be analyzed by Western blotting. Mice of both genders were used.

**Hdh knock-in mouse model of HD.** Dissected brain tissue from Hdh knock-in mice with different polyQ lengths were a kind gift from Dr. Peter Detoff (University of Alabama at Birmingham, Birmingham, AL). The knock-in mice were as described by Kumar et al. (2016). The tissue was homogenized in RIPA buffer and analyzed by Western blotting.

**Statistical analysis.** GraphPad Prism 5 software was used to generate the graphs in this study. For RT-PCR, Kodak 1D Software was used to quantify the intensity of the bands, which were normalized to that of housekeeping genes. For Western blots, ImageJ software was used to calculate the area and intensity of the bands. The intensity of the bands was then normalized with the loading control. Statistical analysis was performed by an unpaired two-tailed Student's *t* test for sample sizes  $< 5$  ( $n = 5$ ). For larger sample sizes, the Mann-Whitney

*U* test was used to calculate the significance level. For comparing more than two datasets, one-way ANOVA with post-test analysis was performed. The results are displayed as mean  $\pm$  SD. For viability experiments, the transfections were performed in duplicate and the experiments were repeated at least three times, and  $> 200$  cells were counted for each condition. The *p* values  $< 0.05$  were considered as statistically significant, and asterisks in figure legends indicate the *p* values as follows: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

**Animal usage.** All procedures conducted using animals were reviewed and approved by the Southern Methodist University Institutional Animal Care and Use Committee.

## Results

### *Foxp1* is highly expressed in the cortex and striatum

To examine the expression of *Foxp1* in the adult mouse brain, we performed Western blots. *Foxp1*-isoform-A (~90 kDa) is expressed widely, but with highest expression in the striatum and cortex (Fig. 1). This is consistent with the results of previous studies (Desplats et al., 2006, 2008; Tang et al., 2012). In addition

**Table 2. Summary of neuropathology and clinical diagnosis of human caudate tissue from NeuroBioBank**

NeuroBioBank sample ID	Age (years)	Gender	Postmortem interval	HD Vonsattel grade	Neuropathology	Other pathology
13082	41	Male	27 h	n.a.	Normal	n.d.
4340	47	Male	12.5 h	n.a.	Normal	Esophageal cancer with metastases to liver
4615	49	Male	15 h	n.a.	Normal	Colon cancer with metastases to liver
13058	50	Male	8 h	n.a.	Normal	n.d.
13069	53	Male	25 h	n.a.	Normal	n.d.
4827	55	Male	11.4 h	n.a.	Normal	Schizophrenia, Tourette's syndrome
13106	59	Male	5 h	n.a.	Normal	n.d.
HCtZU_16_08	62	Male	29 h	n.a.	Normal	n.d.
2983	30	Male	2 h	NG	HD	Early Huntington's disease
2706	43	Male	17 h	1–2	HD	Dementia
4518	49	Male	12.7 h	3	HD	Dementia, ataxia
2858	50	Male	12 h	2	HD	n.d.
3573	51	Male	32 h	3	HD	n.d.
4254	53	Male	9.3 h	3	HD	Depression, dementia, pneumonia
3744	55	Male	19 h	1–2	HD	n.d.
2488	59	Male	9.5 h	4	HD	n.d.
5293	41	Female	11.5 h	n.a.	Normal	Liver failure, pneumonia
4836	52	Female	15.1 h	n.a.	Normal	Depression, suicide, ethanol abuse
3175	54	Female	21.5 h	n.a.	Normal	Pancytopenia, diabetes type I, hypothyroidism
4715	55	Female	4 h	n.a.	Normal	n.d.
3558	59	Female	19.5 h	n.a.	Normal	Lymphoma, non-Hodgkins
HBJO_16_01	67	Female	21 h	n.a.	Normal	Asperger's disorder, opioid abuse
HCtYD_16_01	68	Female	19 h	n.a.	Normal	n.d.
HCtZZ_16_01	82	Female	14 h	n.a.	Normal	n.d.
3383	40	Female	13 h	1	HD	n.d.
2669	44	Female	11 h	NG	HD	Advanced Huntington's disease
HBGY_16_01	48	Female	32 h	NG	HD	Dementia, depression, malnutrition
4072	50	Female	16.3 h	2	HD	Breast cancer
HBLF_16_01	62	Female	14 h	NG	HD	n.d.
HBCS_16_01	68	Female	43 h	NG	HD	n.d.
HBDY_16_01	73	Female	15 h	NG	HD	n.d.
HBFO_16_01	80	Female	38 h	NG	HD	n.d.

n.d., Not determined; n.a., not applicable; NG, No grade.

to isoform-A, expression of two other *Foxp1* isoforms is clearly detectable in the brain. These have previously been designated as isoform-C (~50 kDa) and isoform-D (~70 kDa; Brown et al., 2008; Green et al., 2009; Santos et al., 2011). Isoform-D is also expressed selectively in the striatum and cortex and, in fact, more so than isoform-A (Fig. 1). Isoform-C is expressed at lower levels and in a pattern that is different from the two larger isoforms with expression in the hippocampus and other brain parts, but not cortex (Fig. 1).


#### ***Foxp1* expression is reduced in cortical neurons exposed to oxidative stress**

Oxidative stress is an underlying feature in several neurodegenerative diseases, including HD (Johri and Beal, 2012; Schapira et al., 2014). Cortical neurons are particularly sensitive to oxidative stress and die when exposed to HCA (Ratan et al., 1994). *Foxp1* mRNA and protein expression is reduced in HCA-treated neurons, and this occurs well before neuronal death is observed (Fig. 2A–D). The reduction in mRNA suggests that the downregulation occurs at the transcriptional level. Whereas *Foxp1* expression was reduced, the expression of c-jun, commonly used as a marker of neuronal death, was increased by HCA (Fig. 2A). Although expressed in cultured CGNs at a low level, *Foxp1* expression is not reduced during LK-induced death (Fig. 2E,F). This suggests that expression of *Foxp1* during neuronal death is regulated cell-specifically.

#### ***Foxp1* expression is reduced in the striatum of HD mice and patients**

Since *Foxp1* is selectively expressed in the striatum and cortex, the same brain regions that are selectively affected in HD, we looked at the expression of *Foxp1* in the brains of R6/2 mice, a widely used transgenic mouse model of HD (Bates et al., 1997). The expression of isoform-A and -D were dramatically reduced in the striatum and cortex (Fig. 3A). We and others have previously described that motor deficits in R6/2 mice can be observed at ~7 weeks and, thus, *Foxp1* downregulation in the R6/2 brain occurs before motor deficits are obvious. The downregulation was selective for the striatum and cortex because no reduction was observed in the cerebellum or other brain parts (Fig. 3C,D). *Foxp1* expression in the striatum of R6/2 was comparable to wild-type mice at 2 weeks of age (Fig. 3B), arguing against a developmental effect of expression and indicating that the reduction in *Foxp1* may trigger disease pathogenesis. In support of this conclusion, *Foxp1* expression levels were also decreased in striatum of *Hdh* knock-in mice (Fig. 3F) but not to a significant extent in the cortex and cerebellum (Fig. 3E,G). The reduction in *Foxp1* protein levels in the striatum of these mice correlated with the increase in length of the polyglutamine expansion, which previous studies have shown correlates with disease severity (Fig. 3H; Kumar et al., 2016). In addition to our own studies, microarray analyses conducted by other groups also list *Foxp1* as one of the genes that is significantly downregulated in various mouse HD





**Figure 5.** Suppression of *Foxp1* expression induces apoptosis in healthy neurons. **A**, RNA was collected from cortical neurons infected with lentivirus generated from shRNA constructs (shA–shE) to knock down *Foxp1* expression or by lentivirus Plk0.1 as control.  $\beta$ -Actin is used as the normalization control. **B**, Cortical neurons were cotransfected with Plk0.1 (control) or shRNA plasmids and GFP in a ratio of 6.5:1 for 72 h. Immunocytochemistry was performed using a GFP antibody to identify the transfected cells, and viability was determined by DAPI staining.  $^{**}p < 0.01$  ( $n = 3$ ), compared with the viability of cells transfected with Plk0.1. Data are expressed as mean  $\pm$  SD. **C**, CRISPR plasmids CPR-1, CPR-2, and CPR-3 and a vector control (PX-458) were transfected into N2A cells for 48 and 72 h. Protein lysates were collected and analyzed by Western blotting using Foxp1 antibody (Cell Signaling Technology). Erk1/2 is used as the loading control. **D**, Cortical neurons were transfected with PX-458 (vector) or CRISPR plasmids CPR-1 and CPR-2 for 72 h, immunocytochemistry was performed using a GFP antibody, and viability was quantified by DAPI staining. Viability was normalized to cortical neurons transfected with PX-458. The data are represented as mean  $\pm$  SD.  $^{**}p < 0.01$ , compared with neurons transfected with PX-458 ( $n = 3$ ). **E**, Cortical neurons were cotransfected with Plk0.1 or shRNA plasmids along with GFP in a ratio of 6.5:1, and 72 h later, immunocytochemistry was performed to detect the endogenous levels of Foxp1 protein using Foxp1 antibody (Cell Signaling Technology) and to determine the efficiency of the shRNA in knocking down Foxp1.

models (Table 1). We extended our analyses to lysates from the caudate of human HD patients and found a dramatic decrease in expression of *Foxp1* mRNA levels, both in males (Fig. 4A) and females (Fig. 4B) compared with age- and gender-matched normal individuals (see Table 2 for sample details). In Western blots, Foxp1 isoform-A and isoform-D were decreased in lysates of HD patients compared with normal controls, whereas expression of isoform-C appeared to be increased (Fig. 4C,D). Reduced *Foxp1* expression has also been described by other laboratories in R6/1 mice, a related HD model (Desplats et al., 2006; Tang et al., 2012). And although expression of *Foxp1* protein has not been studied previously in HD patients, reduction of *Foxp1* mRNA levels in the

HD caudate has been described by another laboratory (Desplats et al., 2006; Tang et al., 2012). It is noteworthy that *Foxp1* expression is not altered in the striatum or substantia nigra of 6-hydroxy dopamine-administered rats, a commonly used model of Parkinson's disease (Tang et al., 2012). Together with the absence of a downregulation in LK-treated CGNs, this observation suggests that *Foxp1* downregulation is both cell type and disease selective.

To examine whether we could recapitulate the downregulation of *Foxp1* expression seen in mouse models (Fig. 3D,H) and human HD patients (Fig. 4E,F) in a cell culture model of HD, we expressed mut-*Htt* in primary cortical neurons and Neuro2A cells, a mouse striatal cell line. As observed in HD mice and patients, substantial downregulation of *Foxp1* was observed in mut-*Htt*-expressing neurons as well as N2A cells (Fig. 4G,H).

#### *Foxp1* is needed for neuronal survival

The downregulation of *Foxp1* isoform-A expression in both oxidatively stressed cortical neurons and degenerating regions of the R6/2 and human HD brain suggests that elevated expression of *Foxp1* isoform-A is necessary for the full survival capacity of neurons. To investigate this possibility, we tested five commercially available shRNAs against *Foxp1* and identified three that reduced *Foxp1* protein levels significantly, designated as shA, shD, and shE (Fig. 5A). Expression of these three shRNAs induced cell death in otherwise healthy cortical neurons (Fig. 5B). In contrast, another shRNA, shC, which was incapable of knocking down *Foxp1* expression, and shB, which only binds to *Foxp1* isoform-A but not to the other isoforms, had no effect on neuronal survival (Fig. 5B). Similarly, when *Foxp1* expression was knocked down using CRISPR/Cas9 technology using two separate guide RNA constructs, CPR-1 and CPR-2, the survival of cortical neurons was reduced (Fig. 5C,D). The knockdown of *Foxp1* was confirmed in cortical neurons by immunocytochemistry using endogenous Foxp1 antibodies (Fig. 5E).

models (Table 1). We extended our analyses to lysates from the caudate of human HD patients and found a dramatic decrease in expression of *Foxp1* mRNA levels, both in males (Fig. 4A) and females (Fig. 4B) compared with age- and gender-matched normal individuals (see Table 2 for sample details). In Western blots, Foxp1 isoform-A and isoform-D were decreased in lysates of HD patients compared with normal controls, whereas expression of isoform-C appeared to be increased (Fig. 4C,D). Reduced *Foxp1* expression has also been described by other laboratories in R6/1 mice, a related HD model (Desplats et al., 2006; Tang et al., 2012). And although expression of *Foxp1* protein has not been studied previously in HD patients, reduction of *Foxp1* mRNA levels in the

#### Elevating Foxp1 levels protects against mut-*Htt* neurotoxicity

Whereas reduced *Foxp1* expression results in loss of neuronal viability, restoring elevated levels of *Foxp1* isoform-A by ectopic expression protected cortical neurons from HCA-induced death (Fig. 6A) and against mut-*Htt* neurotoxicity (Fig. 6B). The two domains essential for *Foxp1* transcriptional activity are the LZ and the FH domains. We, therefore, generated mutant forms of *Foxp1* lacking these two domains, *Foxp1* $\Delta$ LZ and *Foxp1* $\Delta$ FH, and tested their ability to protect against mut-*Htt* neurotoxicity.




When ectopically expressed in neurons, *Foxp1* $\Delta$ LZ maintains a nuclear localization like wild-type *Foxp1* whereas *Foxp1* $\Delta$ FH, which lacks the nuclear localization signal, shows a cytoplasmic localization (Fig. 6C). Neither of these mutant constructs could protect against mut-*Htt* neurotoxicity (Fig. 6B).

As shown in Figure 2, E and F, *Foxp1* is expressed relatively weakly in CGNs, and its expression is not reduced in these neurons when cell death is induced by LK treatment. Yet, the overexpression of *Foxp1* completely prevents LK-induced death of CGNs (Fig. 6D). This indicates that *Foxp1* is a bona fide neuroprotective protein.

Virtually nothing is known about the functional significance of the smaller isoforms of *Foxp1* in the nervous system. Because *Foxp1* isoform-D is also down-regulated in the striatum of patients and R/2 mice, we investigated whether it was also capable of protecting neurons. As shown in Figure 6B, *Foxp1* isoform-D also protected cortical neurons against mut-*Htt* toxicity.

### *Foxp1* stimulates *p21*<sup>Waf1/Cip1</sup> expression and inhibits cell-cycle progression

Tang et al. (2012) conducted an RNA-Seq analysis to identify genes regulated by *Foxp1* isoform-A overexpression in cultured striatal neurons. One of the genes identified in that screen was *CDKN1A*, which encodes the cell-cycle inhibitory protein *p21*<sup>Waf1/Cip1</sup> (Tang et al., 2012). Interestingly, a separate RNA-Seq study of the striatum of *Foxp1*<sup>+/-</sup> mice also identified *p21*<sup>Waf1/Cip1</sup> as a gene that was positively regulated by *Foxp1* (Araujo et al., 2015). We and several other laboratories have previously described neuroprotective effects of *p21*<sup>Waf1/Cip1</sup>, including protection against mut-*Htt* toxicity (Poluha et al., 1996; Tomita et al., 2006; Harms et al., 2007; Langley et al., 2008; Ma et al., 2013; Mallick and D'Mello, 2014). We, therefore, investigated whether *Foxp1* exerts its neuroprotective effect through stimulation of *p21*<sup>Waf1/Cip1</sup>. Overexpression of *Foxp1* isoform-A in striatally derived N2A cells led to an increase in *p21*<sup>Waf1/Cip1</sup> protein expression (Fig. 7A). In contrast, *Foxp1* mutants *Foxp1* $\Delta$ LZ and *Foxp1* $\Delta$ FH failed to stimulate *p21*<sup>Waf1/Cip1</sup>. Like *Foxp1* isoform-A, expression of *Foxp1* isoform-D also increased *p21*<sup>Waf1/Cip1</sup> expression, whereas *Foxp1* isoform-C had no effect (Fig. 7A). *Foxp1* stimulated expression of *p21*<sup>Waf1/Cip1</sup> in cortical neurons both under normal and apoptotic conditions (Fig. 7B). Similar results were obtained in CGNs upon overexpression (Fig. 7C). If stimulation of *p21*<sup>Waf1/Cip1</sup> is necessary for neuroprotection by *Foxp1*, then knockdown of *p21*<sup>Waf1/Cip1</sup> would be expected to abolish the ability of *Foxp1* to protect. Indeed, knocking down *p21*<sup>Waf1/Cip1</sup> using two separate shRNA constructs blocked the ability of *Foxp1* to protect neurons from cell death (Fig. 7D). To examine whether *p21*<sup>Waf1/Cip1</sup> was a direct target of *Foxp1*, we performed transcrip-




**Figure 6.** Overexpression of *Foxp1* protects neurons from apoptosis. **A**, Cortical neurons were transfected with *GFP* or *Foxp1* for 24 h and treated with medium with or without 1 mM HCA for another 24 h. Viability of transfected neurons was quantified by DAPI staining, and the viability was normalized to *GFP*-transfected cortical neurons in medium without HCA. The data are represented as mean  $\pm$  SD.  $^{**}p < 0.01$ , compared with neurons transfected with *GFP* and treated with HCA ( $n = 4$ ). UN, Untreated. **B**, Cortical neurons were transfected with either *GFP* alone or *GFP*, *Foxp1A*, *Foxp1D*, *Foxp1* $\Delta$ LZ, and *Foxp1* $\Delta$ FH along with Q138-RFP. After 24 h of transfection, the cells were fixed and immunocytochemistry was performed with GFP and RFP antibodies, and the viability of transfected cells was quantified by DAPI staining. Viability was normalized to neurons transfected with *GFP* alone. The data are represented as mean  $\pm$  SD.  $^{***}p < 0.001$ , compared with *GFP* and Q138-cotransfected cells. **C**, N2A cells were cotransfected with *GFP* or *Foxp1* plasmids along with Q138-RFP, and immunocytochemistry was performed to determine the intracellular localization of the proteins. **D**, CGNs were transfected with *GFP* or *Foxp1* plasmids for 24 h, and the medium was changed to HK or LK medium for another 24 h. Immunocytochemistry was performed with GFP/FLAG antibody to identify the transfected cells, and viability was determined by DAPI staining. Viability was normalized to cells transfected with *GFP* in HK medium. The data are represented as mean  $\pm$  SD.  $^{***}p < 0.001$ , compared with neurons transfected with *GFP* and treated with HK medium ( $n = 6$ ).

tional assays in N2A cells by coexpressing *Foxp1* plasmids with a *p21*<sup>Waf1/Cip1</sup> promoter-Luciferase reporter plasmid. Both *Foxp1* isoform-A and *Foxp1* isoform-D stimulated the activity of the *p21*<sup>Waf1/Cip1</sup> promoter (Fig. 7E).

A large body of evidence suggests that aberrant re-entry into the cell cycle underlies cell loss in neurodegenerative diseases (Becker and Bonni, 2004; Greene et al., 2007). Since *Foxp1* stimulates *p21*<sup>Waf1/Cip1</sup> expression and given that *p21*<sup>Waf1/Cip1</sup> is a strong cell-cycle inhibitor, it was likely that *Foxp1* has an inhibitory effect on the cell-cycle machinery. Indeed, BrdU-incorporation assays indicate that *Foxp1* does inhibit cell-cycle progression in N2A cells (Fig. 8A, B) and in rat primary cortical astrocytes (Fig. 8C).

### *Foxp1* is protective in a *Drosophila* model of HD

To extend our results on *Foxp1*-dependent neuroprotection to an *in vivo* model, we used a *Drosophila* HD model. In these flies, the coding region for an N-terminal *Htt* fragment (amino acids 1–170) containing 120 CAG repeats is fused to the GMR promoter, resulting in expression in the eye (Jackson et al., 1998). Although the eye develops normally in these flies, they develop severe photoreceptor degeneration as they age (Jackson et al.,



**Figure 7.** Foxp1 induces the expression of p21. **A**, N2A cells were transfected with GFP or Foxp1 plasmids for 24 h. The protein lysates were subjected to Western blotting with p21 antibody. Erk1/2 was used as the loading control. **B**, Adenovirus for GFP or Foxp1 was used to infect cortical neurons, and 48 h later, the neurons were maintained in either normal survival condition or HCA-induced apoptotic condition for 3 h, and protein lysates were collected and subjected to Western blotting with a p21 antibody. Erk1/2 was used as a loading control. **C**, CGNs were infected with GFP or Foxp1 adenovirus, and 48 h later, the protein lysates were collected and subjected to Western blotting with p21 antibody. Erk1/2 was used as a loading control. **D**, p21 shRNA plasmids were cotransfected with GFP or Foxp1-GFP plasmids in cortical neurons for 72 h, and the viability was accessed by immunocytochemistry and DAPI staining. Viability is normalized to cortical neurons transfected with Plk0.1 along with GFP. The data are represented as mean  $\pm$  SD ( $n = 3$ ). **E**, N2A cells were transfected with GFP or Foxp1 plasmids along with a p21 promoter luciferase construct for 24 h. Renilla was used as a transfection control. Promoter activity is expressed as a ratio of firefly luciferase to renilla luciferase. Fold change represents the ratio of p21 promoter activity in experimental transfected cells to p21 promoter activity in GFP-transfected cells. \*\* $p < 0.01$ ; \* $p < 0.05$ , Foxp1 fold induction compared with the fold induction in GFP-transfected cells.

1998). We, therefore, analyzed the degenerative phenotype in 6- and 10-d-old GMR-*Htt* Q120 flies with and without Foxp1 expression. For this analysis, we generated transgenic flies that express UAS constructs of either Foxp1 isoform-D or Foxp1 isoform-A, the two isoforms we found to be reduced in R6/2 mice and HD patients. These UAS constructs can be readily induced by crossing the flies with flies carrying a promoter-GAL4 construct (Brand and Perrimon, 1993). However, inducing their expression in the retina with the strong GMR-GAL4 promoter construct resulted in defects in the development of the eye, rendering them unsuitable for our analysis of age-related degeneration. As an alternative we used *Appl*-GAL4, which induces expression in all neurons (including photoreceptors), but at much lower levels. Indeed, expressing Foxp1 isoform-A or Foxp1 isoform-D with this driver had no detectable effect on the development of the eye (data not shown). Intriguingly, expression of either isoform with *Appl*-GAL4 suppressed the degenerative eye phenotype in GMR-*Htt* Q120 flies. Wild-type flies show a regular pattern of ommatidia in the eye that contains eight photoreceptors (each with its own light-sensitive rhabdomere), but because photoreceptors R7 and R8 are positioned above each other, only seven of the photoreceptors/rhabdomeres are detectable in cross sections (fly was 6 d old; Fig. 9A). In contrast, 6-d-old GMR-*Htt* Q120 control flies (carrying the *Appl*-GAL4 promoter construct) showed a highly disorganized retina, with reduced numbers of rhabdomeres

(Fig. 9B). When we induced UAS-Foxp1 isoform-A (via *Appl*-GAL4) in these flies, their retinas appeared less disrupted and more rhabdomeres were present (Fig. 9C), and a similar result was obtained with UAS-Foxp1 isoform-D (data not shown). To quantify this phenotype, we counted the number of rhabdomeres per ommatidia in each line. Wild-type flies showed an average of 6.6 rhabdomeres (Fig. 9D), close to the expected seven (the difference is most likely attributable to a rhabdomere occasionally not being discernable). GMR-*Htt* Q120 flies with only the *Appl*-GAL4 driver showed a significantly reduced number of rhabdomeres, with an average of 2.5 per ommatidia. Expression of Foxp1 isoform-A or Foxp1 isoform-D increased this number to 4.2 and 4.4, confirming a protective function for both isoforms. When we examined flies that only expressed the Foxp1 constructs, we found no effect on rhabdomere numbers with Foxp1-isoform-D, but Foxp1-isoform-A did show a slight reduction to 6.3 rhabdomeres per ommatidia, which was significantly different compared with wild type (Fig. 9D). Although this construct induced a weak degenerative phenotype, it nevertheless reduced the retinal degeneration caused by mutant *Htt*, showing that both isoforms are protective in combination with *Htt* Q120. A similar protective effect was detected in 10-d-old flies (data not shown) but was more difficult to quantify because of the eye becoming progressively more disrupted with age. Finally, to determine whether the increased

survival of photoreceptor cells also improved visual function, we performed phototaxis assays, which measure behavioral responses to a light source. As expected from the severe retinal degeneration seen in 10-d-old GMR-*Htt* Q120 flies (with *Appl*-GAL4), they showed a significantly reduced performance in this assay (Fig. 9E). In contrast, expressing Foxp1 isoform-A or Foxp1 isoform-D with *Appl*-GAL4 in GMR-*Htt* Q120 flies dramatically increased their performance in this assay. Remarkably, the Foxp1-isoform-D-expressing flies actually performed as well as wild-type flies, revealing a dramatic functional improvement. Inducing Foxp1-isoform-A or Foxp1-isoform-D in the wild-type background did not cause detectable changes in phototaxis behavior.


As a first step to determine whether the protective effects of Foxp1 were specific for *Htt*, we also determined the effects of Foxp1 isoform-A and Foxp1 isoform-D on amyloid  $\beta$  (A $\beta$ )-induced degeneration and behavioral deficits but could not detect significant effects (data not shown). These studies confirm that both of these Foxp1 isoforms have a neuroprotective effect *in vivo*, and they indicate that Foxp1 specifically interacts with *Htt*, supporting the hypothesis that downregulation of Foxp1 is a key event in the pathology of HD.

## Discussion

A defining feature of neurodegenerative diseases is the abnormal loss of neurons for which there is no cure or treatment strategy that can slow down the relentless death of neurons. A number of

genes have been identified whose mutations cause familial forms of many of these diseases. An intriguing but yet unexplained feature about neurodegenerative diseases is the selective nature of neuronal loss. Specifically, although the mutant genes responsible for the various diseases are generally expressed widely in the brain, only specific brain regions and neuronal populations are affected in each disease. One possibility that may explain this selective vulnerability is that the mutant gene may affect, either directly or through other biochemical or metabolic changes, the expression of genes that are selectively expressed in the vulnerable brain regions and that regulate the survival of neurons in these regions. Reduced expression of such region- or cell-specific neuroprotective genes, or increased expression of region- or cell-specific neurotoxic genes, would thus explain the selective vulnerability of specific brain regions. Focusing on HD, we suggest that *Foxp1* is one such gene. In support of this possibility, and as previously described (Desplats et al., 2006, 2008; Tang et al., 2012), we find that *Foxp1* is expressed most highly in the striatum and to a lower level in the cortex of HD mice. Within the striatum, *Foxp1* is expressed only in MSNs, which are the neuronal population that degenerates in HD (Desplats et al., 2006, 2008; Tang et al., 2012). Expression of *Foxp1* is selectively reduced in the striatum and cortex of R6/2 HD mice and even more dramatically in the caudate of human HD patients. Forcibly knocking down *Foxp1* induces death in otherwise healthy cortical neurons, supporting the idea that *Foxp1* is necessary for their survival. In support of our hypothesis that the loss of specific neuronal populations in neurodegenerative diseases is attributable to an effect of the disease gene on molecules selectively expressed in those cell populations, we found that overexpression of mut-*Htt* is sufficient to reduce *Foxp1* expression. Indeed, re-establishment of elevated levels of *Foxp1* protects cultured cortical neurons from mut-*Htt* neurotoxicity. Furthermore, elevated *Foxp1* protects against neuronal loss and improves behavioral performance in a *Drosophila* model of HD. It deserves mention that whereas neurons of the striatum and cortex selectively degenerate, other brain regions and neuronal types are also known to be affected in HD. Further investigation is needed to determine whether *Foxp1* is expressed in these other neuronal types and whether its expression is reduced in these cells in HD. It is quite possible that although *Foxp1* protects cortical and striatal neurons, the survival of other neuronal populations that are affected in HD may be safe-guarded by molecules other than members of the *Foxp* family or by other proteins all together.

The importance of *Foxp* for neuronal function is also supported by the finding that a neuronal knockdown of endogenous *Foxp* in flies causes defects in motor coordination (Lawton et al., 2014). However, whether this may be attributable to neuronal death was not investigated. Together with the protective function of *Foxp1* in flies, this suggests that the neuroprotective function




**Figure 8.** Foxp1 inhibits cell-cycle progression. **A**, N2A cells were transfected with plasmids expressing GFP, *Foxp1*, or *p21<sup>Cip1</sup>/Waf1*, which serves as a positive control for cell-cycle inhibition. BrdU was added to the culture medium 22 h later for 2 h. Immunocytochemistry was performed with GFP or FLAG antibodies to label the transfected cells and BrdU antibodies to label the dividing cells. **B**, **C**, BrdU assay in N2A cells (**B**) and in cortical glial cells (**C**). Percentage of BrdU-positive cells was calculated as BrdU-positive cells per transfected cells. \*\* $p < 0.01$  ( $n = 3$ ), *Foxp1*-transfected cells compared with GFP-transfected N2A cells.

and the molecular pathways that mediate this function are conserved between *Drosophila* and mammals. An intriguing aspect of *Foxp1*-mediated neuroprotection is that although it can protect cultured cortical neurons and CGNs against HCA and LK-induced death, and can protect retinal neurons in *Drosophila* against mut-*Htt* toxicity, it cannot protect retinal neurons against A $\beta$  toxicity. This suggests that *Foxp1* cannot protect neurons in all circumstances. Certain neurotoxic stimuli may activate molecular mechanisms or a form of cell death that *Foxp1* is unable to protect against. In the case of A $\beta$ , it is possible that A $\beta$  induces molecular alterations that *Foxp1* cannot prevent or block the effects of.

Although it is known that the *Foxp1* gene encodes multiple isoforms as a result of alternative splicing, the functional significance of the smaller isoforms of *Foxp1* are poorly understood. Interestingly, isoform-D is even more selectively expressed in the striatum and cortex than *Foxp1* isoform-A and is more robustly downregulated in R6/2 mice than the full-length form. That this isoform is also neuroprotective is shown by our findings that ectopic expression of isoform-D also protects neurons and flies from mut-*Htt* toxicity. Although further investigation is necessary, it is possible that downregulation of isoform-D is even more relevant to HD pathogenesis than downregulation of isoform-A. In contrast to these two other isoforms, isoform-C has a different pattern of expression and its levels are increased in the human HD striatum.





**Figure 9.** *Foxp1* reduces photoreceptor loss in 6-d-old *Htt* Q120-expressing flies. **A–C**, Section through the retina of a 6-d-old wild-type fly (**A**), 6-d-old *GMR-Htt* Q120 fly (**B**), and 6-d-old *GMR-Htt* Q120, *App<sup>1</sup>-GAL4>UAS-Foxp1A* fly (**C**). Some rhabdomeres are indicated by arrows. **D**, Counting the number of rhabdomeres per ommatidia revealed a significant increase from 2.5 rhabdomeres in *GMR-Htt* Q120 to 4.2 when *Foxp1A* was induced and 4.4 when *Foxp1D* was induced. The number of ommatidia analyzed is indicated (4–6 ommatidia were counted per retina and at least 5 flies were used). **E**, The performance in the fast phototaxis assay is reduced in 10-d-old *GMR-Htt* Q120 flies compared with age-matched wild type, and this is also significantly improved by the expression of *Foxp1A* or *Foxp1D*. The number of flies tested is indicated.  $*p < 0.05$ ;  $***p < 0.001$ . All flies were females.

Our results point to *p21<sup>Waf1/Cip1</sup>* as one target of *Foxp1*'s neuroprotective action because elevating *Foxp1* expression results in a stimulation of *p21<sup>Waf1/Cip1</sup>* expression. Several other laboratories have described neuroprotective effects for *p21<sup>Waf1/Cip1</sup>*, including in the context of HD (Poluha et al., 1996; Tomita et al., 2006; Harms et al., 2007; Langley et al., 2008; Ma et al., 2013; Mallick and D'Mello, 2014). It is possible that once stimulated by *Foxp1*, *p21<sup>Waf1/Cip1</sup>* acts by inhibiting cell-cycle progression. Aberrant cell-cycle progression has been described as a contributing factor in a variety of neurodegenerative diseases, including HD (Becker and Bonni, 2004; Greene et al., 2007; Liu et al., 2015). Whereas our results point to *p21<sup>Waf1/Cip1</sup>* as a contributing factor, it is likely that there are other *Foxp1* targets that contribute to its neuroprotective activity in the striatum and cortex. And it is also likely that there are other alterations besides reduced *Foxp1* levels that combined result in HD. Indeed, although mutations in *Foxp1* are associated with autism, speech/language deficiency, motor deficiencies, and mental retardation, they do not result in striatal degeneration or other major pathological features of HD. It may be noted, however, that mutations in other genes, whose reduced functions are widely believed to contribute to HD pathogenesis and considered as therapeutic targets, do not produce HD characteristics either. For example, mutations of BDNF, a molecule whose reduced activity and function are widely believed to contribute to HD, are associated with bulimia, anorexia, and congenital hypoventilation (Weese-Mayer et al., 2002; Ribases et al., 2004, 2005).

How does the presence of mut-*Htt* lead to a reduction in *Foxp1* expression? It is possible that this reduction is mediated by *HDAC3*. We have previously described that *HDAC3* is required for mut-*Htt* neurotoxicity (Bardai and D'Mello, 2011; Bardai et al., 2013). Other laboratories have described beneficial effects of *HDAC3* inhibitors in mouse models of HD (Thomas et al., 2008; Jia et al., 2012). Although expressed in the healthy brain and required for proper brain development, *HDAC3* promotes neuronal death when phosphorylated by *GSK3 $\beta$* , whose increased activity has been noted in HD and other neurodegenerative diseases (Wei et al., 2001; Carmichael et al., 2002; Rangone et al., 2005). Other events that contribute to the transformation of *HDAC3* to a neurotoxic protein include disassociation from wild-type *Htt* and association with *HDAC1* (Bardai et al., 2013).



In summary, we describe for the first time that *Foxp1*, a gene expressed selectively in the striatum and cortex, is neuroprotective. Using both cultured neurons and an *in vivo* model, we present evidence indicating that the downregulation of *Foxp1* in HD contributes to neurodegeneration. We show that a smaller isoform of *Foxp1* is also neuroprotective and likely to be involved in HD pathogenesis. To our knowledge, this is the first attempt to investigate the functions of the smaller isoforms of *Foxp1* in the nervous system. Finally, we suggest that *Foxp1* preserves neuronal viability by stimulating the expression of *p21<sup>Waf1/Cip1</sup>*. We propose that elevating *Foxp1* expression in vulnerable populations either pharmacologically or delivering it using viruses or other biological means could represent an attractive therapeutic approach for HD.

## References

- Araujo DJ, Anderson AG, Berto S, Runnels W, Harper M, Ammanuel S, Rieger MA, Huang HC, Rajkovich K, Loerwald KW, Dekker JD, Tucker HO, Dougherty JD, Gibson JR, Konopka G (2015) FoxP1 orchestration of ASD-relevant signaling pathways in the striatum. *Genes Dev* 29:2081–2096. [CrossRef Medline](#)
- Bacon C, Schneider M, Le Magueresse C, Froehlich H, Sticht C, Gluch C, Monyer H, Rappold GA (2014) Brain-specific Foxp1 deletion impairs neuronal development and causes autistic-like behaviour. *Mol Psychiatry* 20:632–639. [CrossRef Medline](#)
- Bardai FH, D'Mello SR (2011) Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3 $\beta$ . *J Neurosci* 31:1746–1751. [CrossRef Medline](#)
- Bardai FH, Verma P, Smith C, Rawat V, Wang L, D'Mello SR (2013) Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. *J Neurosci* 33:11833–11838. [CrossRef Medline](#)
- Bates GP, Mangiarini L, Mahal A, Davies SW (1997) Transgenic models of Huntington's disease. *Hum Mol Genet* 6:1633–1637. [Medline](#)
- Becker EB, Bonni A (2004) Cell cycle regulation of neuronal apoptosis in development and disease. *Prog Neurobiol* 72:1–25. [Medline](#)
- Benzer S (1967) Behavioral mutants of *Drosophila* isolated by countercurrent distribution. *Proc Natl Acad Sci U S A* 58:1112–1119. [CrossRef Medline](#)
- Bettencourt da Cruz A, Schwärzel M, Schulze S, Niyati M, Heisenberg M, Kretschmar D (2005) Disruption of the MAP1B-related protein FUTSCH leads to changes in the neuronal cytoskeleton, axonal transport defects, and progressive neurodegeneration in *Drosophila*. *Mol Biol Cell* 16:2433–2442. [CrossRef](#)
- Bowers JM, Konopka G (2012) The role of the FOXP family of transcription factors in ASD. *Dis Markers* 33:251–260. [CrossRef](#)
- Brand AH, Perrimon N (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* 118:401–415. [Medline](#)
- Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA, Jack AS, Pulford K, Rosenwald A, Banham AH (2008) Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. *Blood* 111:2816–2824. [CrossRef Medline](#)
- Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002) Glycogen synthase kinase-3 $\beta$  inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. *J Biol Chem* 277:33791–33798. [CrossRef Medline](#)
- Dasen JS, De Camilli A, Wang B, Tucker PW, Jessell TM (2008) Hox repertoires for motor neuron diversity and connectivity gated by a single accessory factor, FoxP1. *Cell* 134:304–316. [CrossRef Medline](#)
- Dastidar SG, Landrieu PM, D'Mello SR (2011) FoxG1 promotes the survival of postmitotic neurons. *J Neurosci* 31:402–413. [CrossRef Medline](#)
- Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. *J Neurochem* 96:743–757. [CrossRef Medline](#)
- Desplats PA, Lambert JR, Thomas EA (2008) Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. *Neurobiol Dis* 31:298–308. [CrossRef Medline](#)
- D'Mello SR, Galli C, Ciotti T, Calissano P (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. *Proc Natl Acad Sci U S A* 90:10989–10993. [CrossRef Medline](#)
- Gabut M, Samavarchi-Tehrani P, Wang X, Slobodenic V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, Nagy A, Wrana JL, Blencowe BJ (2011) An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. *Cell* 147:132–146. [CrossRef Medline](#)
- Green MR, Gandhi MK, Courtney MJ, Marlton P, Griffiths L (2009) Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NF $\kappa$ B activity in follicular lymphoma. *Leuk Res* 33:1699–1702. [CrossRef Medline](#)
- Greene LA, Liu DX, Troy CM, Biswas SC (2007) Cell cycle molecules define a pathway required for neuron death in development and disease. *Biochim Biophys Acta* 1772:392–401. [CrossRef Medline](#)
- Hamdan FF, Daoud H, Rochefort D, Piton A, Gauthier J, Langlois M, Foomani G, Dobrzaniecka S, Krebs MO, Joobar R, Lafrenière RG, Lacaillie JC, Mottion L, Drapeau P, Beauchamp MH, Phillips MS, Fombonne E, Rouleau GA, Michaud JL (2010) De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. *Am J Hum Genet* 87:671–678. [CrossRef Medline](#)
- Harms C, Albrecht K, Harms U, Seidel K, Hauck L, Baldinger T, Hubner D, Kronenberg G, An J, Ruscher K, Meisel A, Dirnagl U, von Harsdorf R, Endres M, Hörtnagl H (2007) Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21(Waf1/Cip1) as a novel mechanism of neuroprotection by glucocorticoids. *J Neurosci* 27:4562–4571. [CrossRef Medline](#)
- Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, Hollingsworth ZR, Collin F, Synek B, Holmans PA, Young AB, Wexler NS, Delorenzi M, Kooperberg C, Augood SJ, Faull RL, et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. *Hum Mol Genet* 15:965–977. [CrossRef Medline](#)
- Horn D, Kapeller J, Rivera-Brugues N, Moog U, Lorenz-Depiereux B, Eck S, Hempel M, Wagenstaller J, Gawthrop A, Monaco AP, et al. (2010) Identification of FOXP1 deletions in three unrelated patients with mental retardation and significant speech and language deficits. *Hum Mutat* 31:E1851–E1860. [CrossRef](#)
- Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL (1998) Polyglutamine-expanded human Huntingtin transgenes induce degeneration of *Drosophila* photoreceptor neurons. *Neuron* 21:633–642. [CrossRef Medline](#)
- Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA (2012) Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. *Neurobiol Dis* 46:351–361. [Medline](#)
- Johri A, Beal MF (2012) Antioxidants in Huntington's disease. *Biochim Biophys Acta* 1822:664–674. [CrossRef Medline](#)
- Konstantoulas CJ, Parmar M, Li M (2010) FoxP1 promotes midbrain identity in embryonic stem cell-derived dopamine neurons by regulating Pitx3. *J Neurochem* 113:836–847. [CrossRef Medline](#)
- Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. *Hum Mol Genet* 16:1845–1861. [CrossRef Medline](#)
- Kumar A, Zhang J, Tallaksen-Greene S, Crowley MR, Crossman DK, Morton AJ, Van Groen T, Kadish I, Albin RL, Lesort M, Detloff PJ (2016) Allelic series of Huntington's disease knock-in mice reveals expression discordance. *Hum Mol Genet* 25:1619–1636. [CrossRef Medline](#)
- Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, Lu XH, Ramos EM, El-Zein K, Zhao Y, Deverasetty S, Tebbe A, Schaab C, Lavery DJ, Howland D, Kwak S, Botas J, Aaronson JS, Rosinski J, Coppola G, et al. (2016) Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. *Nat Neurosci* 19:623–633. [CrossRef](#)
- Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko

- B, Fisher M, Cho S, Beal MF, Ratan RR (2008) Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. *J Neurosci* 28:163–176. [CrossRef Medline](#)
- Lawton KJ, Wassmer TL, Deitcher DL (2014) Conserved role of *Drosophila melanogaster* FoxP in motor coordination and courtship song. *Behav Brain Res* 268:213–221. [CrossRef Medline](#)
- Le Fevre AK, Taylor S, Malek NH, Horn D, Carr CW, Abdul-Rahman OA, O'Donnell S, Burgess T, Shaw M, Gecz J, Bain N, Fagan K, Hunter MF (2013) FOXP1 mutations cause intellectual disability and a recognizable phenotype. *Am J Med Genet A* 161A:3166–3175. [CrossRef Medline](#)
- Li X, Xiao J, Frohlich H, Tu X, Li L, Xu Y, Cao H, Qu J, Rappold GA, Chen JG (2015) Foxp1 regulates cortical radial migration and neuronal morphogenesis in developing cerebral cortex. *PLoS One* 10:e0127671. [CrossRef Medline](#)
- Liu KY, Shyu YC, Barbaro BA, Lin YT, Chern Y, Thompson LM, James Shen CK, Marsh JL (2015) Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease. *Hum Mol Genet* 24:1602–1616. [CrossRef Medline](#)
- Ma TC, Langley B, Ko B, Wei N, Gazaryan IG, Zareen N, Yamashiro DJ, Willis DE, Ratan RR (2013) A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. *Neurobiol Dis* 49:13–21. [CrossRef Medline](#)
- Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR (2008) HDAC4 inhibits cell-cycle progression and protects neurons from cell death. *Dev Neurobiol* 68:1076–1092. [CrossRef](#)
- Mallick S, D'Mello SR (2014) JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression. *J Biol Chem* 289:35409–35420. [CrossRef Medline](#)
- Pariani MJ, Spencer A, Graham JM Jr, Rimoin DL (2009) A 785kb deletion of 3p14.1p13, including the FOXP1 gene, associated with speech delay, contractures, hypertonia and blepharophimosis. *Eur J Med Genet* 52:123–127. [CrossRef Medline](#)
- Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL, Ross AH (1996) The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. *Mol Cell Biol* 16:1335–1341. [CrossRef Medline](#)
- Rangone H, Pardo R, Colin E, Girault JA, Saudou F, Humbert S (2005) Phosphorylation of arfaptin 2 at Ser260 by Akt inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. *J Biol Chem* 280:22021–22028. [CrossRef Medline](#)
- Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apoptosis in embryonic cortical neurons. *J Neurochem* 62:376–379. [Medline](#)
- Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M, Cavallini MC, Cellini E, Di Bella D, Erzegovesi S, Foulon C, Gabbrosek M, Gorwood P, Hebebrand J, Hinney A, Holliday J, Hu X, Karwautz A, Kipman A, Komel R, et al. (2004) Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. *Hum Mol Genet* 13:1205–1212. [Medline](#)
- Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M, Cristina Cavallini M, Cellini E, Di Bella D, Erzegovesi S, Foulon C, Gabbrosek M, Gorwood P, Hebebrand J, Hinney A, Holliday J, Hu X, Karwautz A, Kipman A, Komel R, et al. (2005) Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. *Eur J Hum Genet* 13:428–434. [Medline](#)
- Santos ME, Athanasiadis A, Leita AB, DuPasquier L, Sucena E (2011) Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily. *Mol Biol Evol* 28:237–247. [CrossRef Medline](#)
- Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. *Lancet* 384:545–555. [CrossRef Medline](#)
- Sollis E, Graham SA, Vino A, Froehlich H, Vreeburg M, Dimitropoulou D, Gilissen C, Pfundt R, Rappold GA, Brunner HG, Deriziotis P, Fisher SE (2016) Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder. *Hum Mol Genet* 25:546–557. [CrossRef Medline](#)
- Strauss R, Heisenberg M (1993) A higher control center of locomotor behavior in the *Drosophila* brain. *J Neurosci* 13:1852–1861. [Medline](#)
- Tam WY, Leung CK, Tong KK, Kwan KM (2011) Foxp4 is essential in maintenance of Purkinje cell dendritic arborization in the mouse cerebellum. *Neuroscience* 172:562–571. [CrossRef Medline](#)
- Tamura S, Morikawa Y, Iwanishi H, Hisaoka T, Senba E (2004) Foxp1 gene expression in projection neurons of the mouse striatum. *Neuroscience* 124:261–267. [CrossRef Medline](#)
- Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, Masliah E, Leavitt BR, Thomas EA (2012) Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. *Hum Mol Genet* 21:3097–3111. [CrossRef Medline](#)
- Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, Thomas EA (2011) Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. *Neurobiol Dis* 42:459–467. [CrossRef](#)
- Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld JM (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. *Proc Natl Acad Sci U S A* 105:15564–15569. [CrossRef Medline](#)
- Tomita K, Kubo T, Matsuda K, Madura T, Yano K, Fujiwara T, Tanaka H, Tohyama M, Hosokawa K (2006) p21Cip1/WAF1 regulates radial axon growth and enhances motor functional recovery in the injured peripheral nervous system. *Brain Res* 1081:44–52. [CrossRef Medline](#)
- Wang B, Weidenfeld J, Lu MM, Maika S, Kuziel WA, Morrissey EE, Tucker PW (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. *Development* 131:4477–4487. [CrossRef Medline](#)
- Weese-Mayer DE, Bolk S, Silvestri JM, Chakravarti A (2002) Idiopathic congenital central hypoventilation syndrome: evaluation of brain-derived neurotrophic factor genomic DNA sequence variation. *Am J Med Genet* 107:306–310. [Medline](#)
- Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. *Neuroscience* 106:603–612. [CrossRef Medline](#)
- Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutic targets in Huntington's disease. *Physiol Rev* 90:905–981. [CrossRef Medline](#)